The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...
The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only ...
In a new study, researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs ...
The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
Pharmaceuticals announced that the U.S. FDA has approved Revuforj as the first and only menin inhibitor for the treatment of ...
Opens in a new tab or window The FDA declined to grant full approval to obeticholic ... Notably, the FDA this year granted ...
The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with ...
The Food and Drug Administration approved Revuforj from Syndax (SNDX) Pharmaceuticals, a menin inhibitor, for relapsed or refractory acute ...
Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...
The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...
Earlier this year, the FDA approved 2 new indications for Aquaflor. According to Merck, the supplemental approval increased ...
If companies fail to promptly undertake confirmatory trials post-approval, this could compromise the robustness of evidence ...